PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤の世界市場レポート 2024年

PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤の市場規模は近年急速に拡大しています。2023年の398億米ドルから2024年には462億9,000万米ドルへと、CAGR16.3％で拡大します。過去数年間に見られた成長は、主にいくつかの重要な要因によるものです。このうち、免疫療法の著しい進歩は、臨床的成功率の顕著な向上とその後の承認に顕著に表れています。さらに、がんの罹患率の増加もこの成長軌道に大きく寄与しています。さらに、免疫療法のような革新的なアプローチにより重点を置くという、がんの治療パラダイムの顕著な変化も極めて重要な役割を果たしています。業界内の協力関係や研究への多額の投資は、がん治療の進歩をさらに推進し、この期間に観察された全体的な成長に大きく寄与しています。

PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場規模は、今後数年で急成長が見込まれます。2028年には年間平均成長率（CAGR）14.7％で801億米ドルに成長します。予測期間の成長は、特に治療の適応拡大、バイオマーカー研究への注目の高まり、個別化医療の登場など、さまざまな要因に起因しています。予後はまた、臨床試験や共同研究への取り組みの増加、世界のヘルスケアインフラの継続的な開発にも影響されます。

免疫チェックポイント阻害剤としても知られるPD-1およびPD-L1阻害剤市場の成長予測は、がん患者の有病率の上昇に大きく影響されています。制御不能な細胞増殖と拡散を特徴とするがんは、近年顕著に増加しています。PD-1阻害剤とPD-L1阻害剤は、がん細胞と効果的に闘うために身体の免疫システムを活用することで、がん治療に重要な役割を果たしています。例えば、EUサイエンス・ハブが2023年10月に発表した調査結果によると、過去2年間に新たに発生したがん患者は2.3％増の274万人に達し、がん関連死は2.4％増加しました。このがん罹患率の急増は、PD-1およびPD-L1阻害剤市場の成長予測に大きく寄与しています。

PD-1およびPD-L1阻害剤市場の成長予測は、個別化医療の重視の高まりと密接に結びついています。この高度なヘルスケア・アプローチは、治療戦略において遺伝、行動、環境の影響といった患者固有の要因を考慮するものです。PD-1およびPD-L1阻害剤の文脈では、個別化医療は、個々の患者の特性やバイオマーカーの発現に基づき、有効性を最適化し、潜在的な副作用を最小化するためにがん治療を調整することを含みます。2023年2月に発表された個別化医療連合のデータによると、2022年に米国FDAが新たに承認した医薬品の34％が個別化医療によるものであり、持続的な増加傾向を示しています。このような個別化医療への注目の高まりは、PD-1およびPD-L1阻害剤市場を大きく前進させる。

北米は、2023年のPD-1およびPDL1阻害剤市場において最大の地域でした。PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、製品別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ニボルマブ
• ペンブロリズマブ
• アテゾリズマブ
• アベルマブ
• デュルバルマブ
• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 肺がん
• 膀胱がん
• 黒色腫
• ホジキンリンパ腫
• 結腸直腸がん
• その他の用途
• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、エンドユーザー別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• 専門クリニック
• 学術研究機関

第7章 地域および国の分析

• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、地域別、実績および予測、2018年から2023年、2023年から2028年、2033年
• 世界のPD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場の競合情勢
• PD-1およびPDL1阻害剤/免疫チェックポイント阻害剤市場の企業プロファイル
  • Bristol-Myers Squibb Company
  • Merck and Company
  • F. Hoffmann-La Roche AG
  • Sanofi SA
  • Amgen Inc.

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

“PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Product: Nivolumab; Pembrolizumab; Atezolizumab; Avelumab; Durvalumab
• 2) By Distribution Channel: Hospital pharmacies; Retail pharmacies; Online pharmacies
• 3) By Application: Lung Cancer; Bladder Cancer; Melanoma; Hodgkin Lymphoma; Colorectal Cancer; Other Applications
• 4) By End-Users : Hospitals; Specialty Clinics; Academic and Research Institutions
• Companies Mentioned: Bristol-Myers Squibb Company; Merck and Company; F. Hoffmann-La Roche AG; Sanofi S.A.; Amgen Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

PD-1 and PDL1 inhibitors, also known as immune checkpoint inhibitors, belong to the class of immunotherapy drugs employed in cancer treatment. They function by directing the immune system to identify and combat cancer cells effectively. Widely applied across various cancer conditions, these therapies serve as vital components in cancer treatment protocols.

Key products within the PD-1 and PDL1 inhibitor category include nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Nivolumab, specifically a PD-1 inhibitor, operates by impeding the PD-1 receptor present on T cells, thereby thwarting cancer cells' ability to evade immune system attacks. These inhibitors find application in treating a spectrum of cancers such as lung cancer, bladder cancer, melanoma, Hodgkin lymphoma, colorectal cancer, among others.

These immunotherapy drugs are available through various channels including hospital pharmacies, retail pharmacies, and online platforms. They are predominantly utilized within hospital settings, specialty clinics, as well as academic and research institutions, constituting integral elements in comprehensive cancer care and research endeavors.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $39.8 billion in 2023 to $46.29 billion in 2024 at a compound annual growth rate (CAGR) of 16.3%. The growth observed in the historical period can be primarily attributed to several key factors. Among these are significant advancements in immunotherapy, marked by notable progress in clinical success rates and subsequent approvals. Moreover, the increased incidence of cancer has also contributed significantly to this growth trajectory. Additionally, a notable shift in the treatment paradigm for cancer, marked by a greater emphasis on innovative approaches such as immunotherapy, has played a pivotal role. Collaborations within the industry and substantial investments in research have further propelled advancements in cancer treatment, contributing significantly to the overall growth observed during this period.

The pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market size is expected to see rapid growth in the next few years. It will grow to $80.1 billion in 2028 at a compound annual growth rate (CAGR) of 14.7%. Anticipated growth in the forecast period stems from various factors, notably the expansion of indications for treatments, heightened focus on biomarker research, and the advent of personalized medicine. The prognosis is also influenced by increased engagement in clinical trials and research collaborations, alongside ongoing development in global healthcare infrastructure.

The projected growth in the PD-1 and PD-L1 Inhibitors, also known as Immune Checkpoint Inhibitors, market is heavily influenced by the escalating prevalence of cancer cases. Cancer, characterized by uncontrolled cell growth and dissemination, has seen a noticeable increase in cases over recent years. PD-1 and PD-L1 inhibitors play a crucial role in treating cancer by leveraging the body's immune system to combat cancer cells effectively. For example, as per the European Union Science Hub's findings in October 2023, the preceding two years witnessed a 2.3% rise in new cancer cases, reaching 2.74 million, alongside a 2.4% increase in cancer-related deaths. This surge in cancer incidence significantly contributes to the growth anticipated in the PD-1 and PD-L1 Inhibitors market.

The anticipated growth in the PD-1 and PD-L1 Inhibitors market is closely tied to the increasing emphasis on personalized medicine. This advanced healthcare approach considers unique patient factors such as genetics, behaviors, and environmental influences in treatment strategies. In the context of PD-1 and PD-L1 inhibitors, personalized medicine involves tailoring cancer therapies to optimize efficacy and minimize potential adverse effects based on individual patient characteristics and biomarker expressions. Notably, the Personalized Medicine Coalition's data from February 2023 revealed that personalized medications accounted for 34% of newly approved pharmaceuticals by the US FDA in 2022, showcasing a sustained upward trend. This growing focus on personalized medicine significantly drives the PD-1 and PD-L1 Inhibitors market forward.

Product innovation has emerged as a pivotal trend shaping the landscape of PD-1 and PD-L1 Inhibitors, or immune checkpoint inhibitors. Leading market players are strategically channeling efforts towards developing innovative products to bolster their market presence. For instance, Bristol-Myers Squibb's successful FDA approval for Opdualag in March 2022 marked a breakthrough-a fixed-dose combination of nivolumab (Opdivo) and relatlimab, the latter being a LAG-3 inhibitor. Opdualag, the first LAG-3 inhibitor approved by the US FDA for treating metastatic melanoma, aims to augment immune responses against cancer cells, showcasing a substantial leap in product innovation within this sector.

Strategic investments play a crucial role in shaping the landscape of the PD-1 and PD-L1 Inhibitors market. Major companies operating in this domain are leveraging strategic initiatives to fortify their positions. For instance, Regeneron Pharmaceuticals, Inc.'s investment in June 2022 involved acquiring Sanofi's share in the Regeneron and Sanofi partnership concerning Libtayo (cemiplimab). This strategic move conferred Regeneron exclusive rights to develop, market, and manufacture Libtayo globally. Valued at $900 million, plus royalties and potential future milestone payments, this investment aimed to bolster Regeneron's foothold in the market. Libtayo, a first-in-class PD-1 inhibitor developed using Regeneron's VelocImmune technology, gained approval from the FDA and numerous global regulatory bodies, solidifying its position as a standard treatment for certain advanced non-small cell lung cancer, cutaneous squamous cell carcinoma, and basal cell carcinoma cases.

In January 2021, Biond Biologics, an Israel-based clinical-stage biopharmaceutical firm, forged a strategic partnership with Sanofi AG, a leading pharmaceutical and healthcare company headquartered in France. The primary objective of this alliance revolves around advancing the development and commercialization of BND-22, a pioneering immune checkpoint inhibitor designed specifically to target the ILT2 receptor. This collaborative venture strongly resonates with Biond's overarching strategy of cultivating impactful partnerships with prominent entities within the biopharmaceutical realm. By synergizing the collective expertise and resources of both entities, this collaboration is poised to deliver substantial value for shareholders while advancing the potential of BND-22 in the market.

Major companies operating in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Bristol-Myers Squibb Company, Merck and Company, F. Hoffmann-La Roche AG, Sanofi S.A., Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, Novartis AG, Pfizer Inc., GlaxoSmithKline Plc, Regeneron Pharmaceuticals Inc., BeiGene Ltd., Shanghai Jhunsi Biosciences Ltd., Akeso Inc., Alphamab Oncology, Eli Lilly and Company, Boehringer Ingelheim, Xencor Inc., Taiga Biotechnologies Inc., Jiangsu Alphamab Biopharmaceuticals Co. Ltd., Dr. Reddy's Laboratories Ltd., Laekna Therapeutics, Genentech Inc., Tracon Pharmaceuticals Inc., Celgene, Hangzhou Sumgen Co. Ltd., Agenus Inc., BioNTech SE, Celldex Therapeutics Inc., CytomX Therapeutics Inc.

North America was the largest region in the PD-1 and PDL1 inhibitors market in 2023. The regions covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the pd-1 and pdl1 inhibitors/ immune checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The PD-1 and PDL1 Inhibitors/ Immune checkpoint inhibitors market consists of sales of various inhibitors such as cemiplimab, sintilimab, and camrelizumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Characteristics

3. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Trends And Strategies

4. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On the Market
• 4.2. Ukraine-Russia War Impact On the Market
• 4.3. COVID-19 Impact On the Market

5. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Size and Growth

• 5.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Segmentation

• 6.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Nivolumab
• Pembrolizumab
• Atezolizumab
• Avelumab
• Durvalumab
• 6.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
• 6.3. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Lung Cancer
• Bladder Cancer
• Melanoma
• Hodgkin Lymphoma
• Colorectal Cancer
• Other Applications
• 6.4. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Specialty Clinics
• Academic and Research Institutions

7. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Regional And Country Analysis

• 7.1. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 8.1. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 9.1. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 9.2. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 10.1. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 11.1. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 11.2. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 12.1. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 13.1. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 14.1. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 14.2. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 15.1. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 15.2. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 16.1. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 17.1. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 18.1. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 19.1. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 20.1. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 21.1. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 21.2. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 22.1. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 23.1. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 23.2. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 24.1. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 24.2. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 25.1. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 25.2. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 26.1. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 26.2. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 27.1. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 28.1. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 28.2. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

• 29.1. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Overview
• 29.2. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Landscape
• 30.2. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Company Profiles
  • 30.2.1. Bristol-Myers Squibb Company
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Merck and Company
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. F. Hoffmann-La Roche AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Sanofi S.A.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Amgen Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Benchmarking

32. Global PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Competitive Dashboard

33. Key Mergers And Acquisitions In The PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market

34. PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market Future Outlook and Potential Analysis

• 34.1 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2028 - Countries Offering Most New Opportunities
• 34.2 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2028 - Segments Offering Most New Opportunities
• 34.3 PD-1 and PDL1 Inhibitors/ Immune Checkpoint Inhibitors Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer